CSNK2A1

Summary

CSNK2A1 (casein kinase 2 alpha 1, HGNC:2457) is a protein-coding gene on chromosome 20p13, encoding Casein kinase II subunit alpha (P68400). Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine.

Casein kinase II is a serine/threonine protein kinase that phosphorylates acidic proteins such as casein. It is involved in various cellular processes, including cell cycle control, apoptosis, and circadian rhythm. The kinase exists as a tetramer and is composed of an alpha, an alpha-prime, and two beta subunits. The alpha subunits contain the catalytic activity while the beta subunits undergo autophosphorylation. The protein encoded by this gene represents the alpha subunit. Multiple transcript variants encoding different protein isoforms have been found for this gene.

Source: NCBI Gene 1457 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic intellectual disability (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 5
• Clinical variants (ClinVar): 281 total — 35 pathogenic, 35 likely-pathogenic
• Druggable target: yes — 36 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_177559

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2457
Approved symbol	CSNK2A1
Name	casein kinase 2 alpha 1
Location	20p13
Locus type	gene with protein product
Status	Approved
Aliases	Cka1, Cka2
Ensembl gene	ENSG00000101266
Ensembl biotype	protein_coding
OMIM	115440
Entrez	1457

Gene structure

Transcript identifiers

Ensembl transcripts: 68 — 50 protein_coding, 14 retained_intron, 4 nonsense_mediated_decay

ENST00000217244, ENST00000349736, ENST00000400217, ENST00000400227, ENST00000460062, ENST00000608066, ENST00000608490, ENST00000609525, ENST00000609606, ENST00000619801, ENST00000642160, ENST00000642673, ENST00000642689, ENST00000643600, ENST00000643602, ENST00000643641, ENST00000643660, ENST00000643680, ENST00000643700, ENST00000643910, ENST00000643968, ENST00000643980, ENST00000644003, ENST00000644170, ENST00000644177, ENST00000644448, ENST00000644710, ENST00000644885, ENST00000645091, ENST00000645187, ENST00000645234, ENST00000645249, ENST00000645260, ENST00000645334, ENST00000645623, ENST00000645641, ENST00000645768, ENST00000645840, ENST00000645910, ENST00000646305, ENST00000646443, ENST00000646477, ENST00000646561, ENST00000646814, ENST00000646908, ENST00000647026, ENST00000647155, ENST00000647348, ENST00000858421, ENST00000858422, ENST00000858423, ENST00000858424, ENST00000858425, ENST00000858426, ENST00000858427, ENST00000858428, ENST00000858429, ENST00000858430, ENST00000922657, ENST00000922658, ENST00000922659, ENST00000922660, ENST00000922661, ENST00000922662, ENST00000948675, ENST00000948676, ENST00000948677, ENST00000948678

RefSeq mRNA: 5 — MANE Select: NM_177559 NM_001362770, NM_001362771, NM_001895, NM_177559, NM_177560

CCDS: CCDS13003, CCDS13004

Canonical transcript exons

ENST00000217244 — 14 exons

Exon	Start	End
ENSE00000655087	486376	486462
ENSE00000655088	487427	487575
ENSE00000655089	488678	488778
ENSE00001387136	527933	528049
ENSE00001709328	508451	508660
ENSE00003461081	497721	497780
ENSE00003493190	505118	505229
ENSE00003533811	492254	492364
ENSE00003598248	499833	499934
ENSE00003601224	495719	495802
ENSE00003670561	499255	499305
ENSE00003676631	489780	489881
ENSE00003819107	472498	484076
ENSE00003829049	543672	543790

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 98.04.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 51.1882 / max 385.0800, expressed in 1821 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
185975	26.9510	1811
185974	21.7593	1808
185976	1.9317	1074
185973	0.5462	302

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.04	gold quality
ganglionic eminence	UBERON:0004023	97.88	gold quality
ventricular zone	UBERON:0003053	97.58	gold quality
colonic epithelium	UBERON:0000397	97.38	gold quality
adrenal tissue	UBERON:0018303	97.06	gold quality
embryo	UBERON:0000922	96.39	gold quality
gingival epithelium	UBERON:0001949	96.04	gold quality
calcaneal tendon	UBERON:0003701	95.96	gold quality
islet of Langerhans	UBERON:0000006	95.88	gold quality
rectum	UBERON:0001052	95.71	gold quality
stromal cell of endometrium	CL:0002255	95.63	gold quality
gastrocnemius	UBERON:0001388	95.46	gold quality
muscle of leg	UBERON:0001383	95.45	gold quality
amniotic fluid	UBERON:0000173	95.32	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.32	gold quality
tonsil	UBERON:0002372	95.16	gold quality
secondary oocyte	CL:0000655	95.08	gold quality
monocyte	CL:0000576	94.90	gold quality
gingiva	UBERON:0001828	94.74	gold quality
mononuclear cell	CL:0000842	94.65	gold quality
gall bladder	UBERON:0002110	94.56	gold quality
leukocyte	CL:0000738	94.51	gold quality
esophagus squamous epithelium	UBERON:0006920	94.11	gold quality
bone marrow cell	CL:0002092	94.04	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.94	gold quality
esophagus mucosa	UBERON:0002469	93.93	gold quality
epithelium of esophagus	UBERON:0001976	93.87	gold quality
smooth muscle tissue	UBERON:0001135	93.86	gold quality
penis	UBERON:0000989	93.84	gold quality
right testis	UBERON:0004534	93.77	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.12

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS1, FOS, HHEX, NFKB1, NFKB, PDX1, RELA, SP1, SP3, TAL1

miRNA regulators (miRDB)

105 targeting CSNK2A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• uPA-dependent VSMC adhesion is a function of selective Vn phosphorylation by the ectoprotein kinase CK2 (PMID:11756447)
• Generation of mutants of CK2alpha which are dependent on the beta-subunit for catalytic activity (PMID:11827164)
• HIV-1 Rev transactivator: a beta-subunit directed substrate and effector of protein kinase CK2 (PMID:11827166)
• Protein kinase CK2: signaling and tumorigenesis in the mammary gland. (PMID:11827167)
• Response of cancer cells to molecular interruption of the CK2 signal. (PMID:11827168)
• Functional specialization of CK2 isoforms and characterization of isoform-specific binding partners (PMID:11827170)
• Characterization of CK2 holoenzyme variants with regard to crystallization (PMID:11827171)
• Transcriptional coordination of the genes encoding catalytic (CK2alpha) and regulatory (CK2beta) subunits of human protein kinase CK2. (PMID:11827174)
• Consequences of CK2 signaling to the nuclear matrix. (PMID:11827176)
• Localization of individual subunits of protein kinase CK2 to the endoplasmic reticulum and to the Golgi apparatus (PMID:11827177)
• Interactions between protein kinase CK2 and Pin1. Evidence for phosphorylation-dependent interactions. (PMID:11940573)
• Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme (PMID:11956194)
• Protein kinase CK2 dependent phosphorylation of the E2 ubiquitin conjugating enzyme UBC3B induces its interaction with beta-TRCp and enhances beta-catenin degradation [UBC3B] (PMID:12037680)
• FGF-1 binds to both the catalytic alpha-subunit and to the regulatory beta-subunit of CK2. FGF-1 & CK2 alpha are shown to interact in vivo. A correlation between the mitogenic potential of FGF-1 mutants & their ability to bind to CK2 alpha was observed. (PMID:12145206)
• Data point to a particular role of the catalytic alpha and alpha’ subunits of protein kinase CK2, which may be different from their roles in the holoenzyme. (PMID:12568341)
• This protein is associated with the COP9 signalosome. (PMID:12628923)
• HSF1 activation by heat is correlated with the thermal activation of nuclear CK2 and overexpression of CK2 activates HSF1 (PMID:12659875)
• results indicate that protein kinase CKII may control IkappaBalpha and p27Kip1 degradation and thereby G1/S phase transition through the phosphorylation of threonine 10 within CKBBP1 protein (PMID:12748192)
• Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit (PMID:12860116)
• Evaluation of different pathways involved in death signaling suggest that the regulation of a critical proapoptotic step in HuH-7 cells by CK2alpha" is mediated by a JNK signaling cascade. (PMID:14962846)
• structure activity relationship: the PA 382-384 mutant exhibits an increased thermal and proteolytic stability (PMID:15108354)
• might play an important role in vivo in regulating the function and transport activity of ABCA1 and possibly of other members of the ABCA subfamily (PMID:15218032)
• Utilizing a kinase-driven assay biochemical purification, the authors identified casein kinase II (CKII) from HeLa cell nuclear extract as a cellular phosphoprotein pp32 kinase. (PMID:15287743)
• CK2 acts as an inhibitor of Cdk5 in the brain (PMID:15342635)
• Involvement of ubiquitous protein kinase CK2 in angiogenesis. Naturally derived CK2 inhibitors may be useful for treatment of proliferative retinopathies. (PMID:15557471)
• CK2 regulates the DNA-binding ability of SSRP1 and that this regulation may be responsive to specific cell stresses. (PMID:15659405)
• Data demonstrate that CK2alpha possesses sophisticated structural adaptations in favour of dual-cosubstrate specificity. (PMID:15740749)
• constitutive phosphorylation by CK2 may be required for maximal activation of Akt/PKB (PMID:15818404)
• CK2 may have the capacity to differentially regulate U1 and U6 transcription even though SNAP(C) is universally utilized for human snRNA gene transcription (PMID:15955816)
• multiple kinases, including CK2 and GSK3beta, participate in PTEN phosphorylation and GSK3beta may provide feedback regulation of PTEN (PMID:16107342)
• Protein kinase CK2 is characterized by an extremely high stability that might be due to its association with other intracellular proteins, enhanced half-life or lower vulnerability towards proteolytic degradation. (PMID:16133877)
• protein kinase CK2 is inactive in CCVs because of the fact that it is bound to the clathrin-coated vesicle (CCV) membrane via an interaction between phosphatidylinositol 4,5-bisphosphate in the CCV membrane and the active site in CK2 (PMID:16157582)
• In vitro phosphorylation of eIF2beta also pointed to Ser2 as a preferred site for CK2 phosphorylation (PMID:16225457)
• CK2 may be involved in the regulation of cell cycle progression by associating with and phosphorylating a key molecule for translation initiation. (PMID:16227438)
• casein kinase 2 induces PACS-1 binding of nephrocystin and targeting to cilia (PMID:16308564)
• CK2 is potentially a highly plausible target for cancer therapy. (PMID:16342410)
• phosphorylation of the (T300) residue is dependent on CK2 and is a necessary and functional prerequisite for TSPY’s transport into the nucleus (PMID:16426576)
• Dynamics of nucleolar reformation is ATP/GTP-dependent, sensitive to temperature, and creatin kinase-2 driven. (PMID:16540521)
• CK2 regulates NKX3-1 in prostate cells. (PMID:16581776)
• Based on its retinal localization, CK2 may be considered a new immunohistochemical astrocytic marker, and combination of CK2 inhibitors and octreotide may be a promising future treatment for proliferative retinopathies. (PMID:16651637)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	csnk2a4	ENSDARG00000091702
mus_musculus	Csnk2a1	ENSMUSG00000074698
rattus_norvegicus	Csnk2a1	ENSRNOG00000005276
drosophila_melanogaster	CkIIalpha	FBGN0264492
caenorhabditis_elegans	kin-3	WBGENE00002191

Paralogs (2): CSNK2A2 (ENSG00000070770), CSNK2A3 (ENSG00000254598)

Protein

Protein identifiers

Casein kinase II subunit alpha — P68400 (reviewed: P68400)

All UniProt accessions (22): P68400, A0A087WY74, A0A2R8Y3W6, A0A2R8Y4D6, A0A2R8Y4H0, A0A2R8Y5A0, A0A2R8Y797, A0A2R8Y7T1, A0A2R8YCC9, A0A2R8YCK2, A0A2R8YD58, A0A2R8YDP2, A0A2R8YDY7, A0A2R8YEL7, A0A2R8YEW1, A0A2R8YF43, A0A2R8YF47, A0A2R8YFU2, E7EU96, V9GY80, V9GYA2, V9GYW6

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating ‘Ser-392’ of p53/TP53 following UV irradiation. Phosphorylates a number of DNA repair proteins in response to DNA damage, such as MDC1, MRE11, RAD9A, RAD51 and HTATSF1, promoting their recruitment to DNA damage sites. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Phosphorylates YY1, protecting YY1 from cleavage by CASP7 during apoptosis. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Mediates sequential phosphorylation of FNIP1, promoting its gradual interaction with Hsp90, leading to activate both kinase and non-kinase client proteins of Hsp90. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at ‘Ser-565’ and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating BMAL1 at ‘Ser-90’ which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry. Phosphorylates CCAR2 at ‘Thr-454’ in gastric carcinoma tissue. Phosphorylates FMR1, promoting FMR1-dependent formation of a membraneless compartment. May phosphorylate histone H2A on ‘Ser-1’.

Subunit / interactions. Heterotetramer composed of two catalytic subunits (alpha chain and/or alpha’ chain) and two regulatory subunits (beta chains). The tetramer can exist as a combination of 2 alpha/2 beta, 2 alpha’/2 beta or 1 alpha/1 alpha’/2 beta subunits. Also part of a CK2-SPT16-SSRP1 complex composed of SSRP1, SUPT16H, CSNK2A1, CSNK2A2 and CSNK2B, which forms following UV irradiation. Interacts with RNPS1. Interacts with SNAI1. Interacts with PML (isoform PML-12). Interacts with CCAR2. Interacts with HIRIP3.

Subcellular location. Nucleus.

Tissue specificity. Expressed in gastric carcinoma tissue and the expression gradually increases with the progression of the carcinoma (at protein level).

Post-translational modifications. Phosphorylated at Thr-344, Thr-360, Ser-362 and Ser-370 by CDK1 in prophase and metaphase and dephosphorylated during anaphase. Phosphorylation does not directly affect casein kinase 2 activity, but may contribute to its regulation by forming binding sites for interacting proteins and/or targeting it to different compartments.

Disease relevance. Okur-Chung neurodevelopmental syndrome (OCNDS) [MIM:617062] An autosomal dominant neurodevelopmental disorder characterized by developmental delay, intellectual disability, behavioral problems, hypotonia, speech problems, microcephaly, pachygyria and variable dysmorphic features. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Constitutively active protein kinase whose activity is not directly affected by phosphorylation. Seems to be regulated by level of expression and localization.

Miscellaneous. Can use both ATP and GTP as phosphoryl donors. Phosphorylation by casein kinase 2 has been estimated to represent up to one quarter of the eukaryotic phosphoproteome. Casein kinase 2 has been found to be increased at protein level and up-regulated at the level of enzyme activity in the majority of cancers. However, elevated levels of casein kinase 2 are present in certain normal organs such as brain and testes.

Similarity. Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. CK2 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P68400-1	1	yes
P68400-2	2

RefSeq proteins (5): NP_001349699, NP_001349700, NP_001886, NP_808227, NP_808228 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR045216	CK2_alpha	Family

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.1 — non-specific serine/threonine protein kinase (BRENDA: 71 organisms, 682 substrates, 228 inhibitors, 23 Km, 6 kcat entries)

Substrate kinetics (BRENDA)

8 substrates with measured Km, best-characterized 8. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0007–0.64	11
KKRAARATSNVFA	0.013–0.045	3
PAH1 PHOSPHATIDATE PHOSPHATASE	0.0002	2
RRRLSSLRA	0.0036–0.0037	2
GTP	0.46	1
KKRAARASSNVFA	0.02	1
LYS-LYS-PHE-ASN-ARG-THR-LEU-SER-VAL-ALA	0.0093	1
MYELIN BASIC PROTEIN	0.145	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (60 total): helix 24, strand 11, turn 6, sequence variant 4, sequence conflict 4, modified residue 4, binding site 2, chain 1, domain 1, splice variant 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

320 structures, top 30 by resolution.

PDB	Method	Resolution (Å)
3WAR	X-RAY DIFFRACTION	1.04
5ZN1	X-RAY DIFFRACTION	1.05
8AEC	X-RAY DIFFRACTION	1.09
7I7Y	X-RAY DIFFRACTION	1.15
6YZH	X-RAY DIFFRACTION	1.19
5ZN2	X-RAY DIFFRACTION	1.2
7I8G	X-RAY DIFFRACTION	1.23
4KWP	X-RAY DIFFRACTION	1.25
5CVG	X-RAY DIFFRACTION	1.25
7I8P	X-RAY DIFFRACTION	1.25
7I8N	X-RAY DIFFRACTION	1.28
8AE7	X-RAY DIFFRACTION	1.28
3NSZ	X-RAY DIFFRACTION	1.3
7I8M	X-RAY DIFFRACTION	1.31
7I8O	X-RAY DIFFRACTION	1.31
7ZWG	X-RAY DIFFRACTION	1.31
7ZYK	X-RAY DIFFRACTION	1.31
7I86	X-RAY DIFFRACTION	1.32
5OUL	X-RAY DIFFRACTION	1.34
7B8H	X-RAY DIFFRACTION	1.34
7I7Z	X-RAY DIFFRACTION	1.35
5CU6	X-RAY DIFFRACTION	1.36
5CSV	X-RAY DIFFRACTION	1.38
7I8K	X-RAY DIFFRACTION	1.38
5MOH	X-RAY DIFFRACTION	1.38
5OTQ	X-RAY DIFFRACTION	1.38
7I8D	X-RAY DIFFRACTION	1.38
7I8H	X-RAY DIFFRACTION	1.39
9QY7	X-RAY DIFFRACTION	1.39
6EHK	X-RAY DIFFRACTION	1.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P68400-F1	90.78	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 156 (proton acceptor)

Ligand- & substrate-binding residues (2): 45–53; 68

Post-translational modifications (4): 344, 360, 362, 370

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-1483191	Synthesis of PC
R-HSA-201688	WNT mediated activation of DVL
R-HSA-2514853	Condensation of Prometaphase Chromosomes
R-HSA-445144	Signal transduction by L1
R-HSA-6804756	Regulation of TP53 Activity through Phosphorylation
R-HSA-6814122	Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
R-HSA-8934903	Receptor Mediated Mitophagy
R-HSA-8939243	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
R-HSA-8948751	Regulation of PTEN stability and activity
R-HSA-9755511	KEAP1-NFE2L2 pathway
R-HSA-9768727	Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
R-HSA-9828806	Maturation of hRSV A proteins
R-HSA-9929491	SPOP-mediated proteasomal degradation of PD-L1(CD274)
R-HSA-9931529	Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
R-HSA-9931530	Phosphorylation and nuclear translocation of the CRY:PER:kinase complex

MSigDB gene sets: 547 (showing top): PID_BCR_5PATHWAY, GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, MODULE_52, GOBP_REGULATION_OF_DNA_RECOMBINATION, GOBP_REGULATION_OF_AUTOPHAGY, GOBP_NEGATIVE_REGULATION_OF_PROTEOLYSIS, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_NEGATIVE_REGULATION_OF_DNA_REPAIR, GOBP_PEPTIDYL_SERINE_MODIFICATION, MATTIOLI_MGUS_VS_PCL, GOBP_NEGATIVE_REGULATION_OF_DNA_RECOMBINATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_GROWTH

GO Biological Process (35): double-strand break repair (GO:0006302), protein folding (GO:0006457), apoptotic process (GO:0006915), DNA damage response (GO:0006974), signal transduction (GO:0007165), positive regulation of cell population proliferation (GO:0008284), Wnt signaling pathway (GO:0016055), negative regulation of translation (GO:0017148), positive regulation of Wnt signaling pathway (GO:0030177), positive regulation of cell growth (GO:0030307), negative regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032435), positive regulation of protein catabolic process (GO:0045732), rhythmic process (GO:0048511), protein stabilization (GO:0050821), regulation of cell cycle (GO:0051726), symbiont-mediated disruption of host cell PML body (GO:0075342), negative regulation of signal transduction by p53 class mediator (GO:1901797), positive regulation of aggrephagy (GO:1905337), regulation of chromosome separation (GO:1905818), negative regulation of double-strand break repair via homologous recombination (GO:2000042), negative regulation of apoptotic signaling pathway (GO:2001234), DNA damage checkpoint signaling (GO:0000077), deadenylation-dependent decapping of nuclear-transcribed mRNA (GO:0000290), double-strand break repair via homologous recombination (GO:0000724), regulation of transcription by RNA polymerase II (GO:0006357), protein phosphorylation (GO:0006468), protein catabolic process (GO:0030163), aggrephagy (GO:0035973), regulation of protein catabolic process (GO:0042176), negative regulation of translational initiation (GO:0045947), protein targeting to vacuole involved in autophagy (GO:0071211), execution phase of apoptosis (GO:0097194), double-strand break repair via classical nonhomologous end joining (GO:0097680), membraneless organelle assembly (GO:0140694), protein localization to site of double-strand break (GO:1990166)

GO Molecular Function (10): protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), kinase activity (GO:0016301), identical protein binding (GO:0042802), Hsp90 protein binding (GO:0051879), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (8): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), protein kinase CK2 complex (GO:0005956), PML body (GO:0016605), Sin3-type complex (GO:0070822), PcG protein complex (GO:0031519)

Reactome top-level categories

Rollup of top-14 pathways:

Category	Pathways
Circadian clock	2
Glycerophospholipid biosynthesis	1
TCF dependent signaling in response to WNT	1
Mitotic Prometaphase	1
L1CAM interactions	1
Regulation of TP53 Activity	1
Chaperonin-mediated protein folding	1
Mitophagy	1
Transcriptional regulation by RUNX1	1
PTEN Regulation	1
Cellular response to chemical stress	1
Regulation of CDH1 Expression and Function	1
Respiratory syncytial virus (RSV) genome replication, transcription and translation	1
Regulation of PD-L1(CD274) Post-translational modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	2
regulation of cellular process	2
positive regulation of cellular process	2
protein kinase activity	2
cellular anatomical structure	2
DNA repair	1
protein maturation	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
cell communication	1
signaling	1
cellular response to stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
cell surface receptor signaling pathway	1
translation	1
regulation of translation	1
negative regulation of gene expression	1
negative regulation of protein metabolic process	1
positive regulation of signal transduction	1
Wnt signaling pathway	1
regulation of Wnt signaling pathway	1
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
regulation of proteasomal ubiquitin-dependent protein catabolic process	1
proteasome-mediated ubiquitin-dependent protein catabolic process	1
negative regulation of proteasomal protein catabolic process	1
negative regulation of ubiquitin-dependent protein catabolic process	1
positive regulation of catabolic process	1
protein catabolic process	1
regulation of protein catabolic process	1
positive regulation of protein metabolic process	1
biological_process	1
regulation of protein stability	1
cell cycle	1
symbiont-mediated disruption of host cellular anatomical structure	1
signal transduction by p53 class mediator	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

743 interactions, top by confidence:

A	B	Type	Score
CSNK2A1	CSNK2B	psi-mi:“MI:0407”(direct interaction)	0.980
CSNK2A1	CSNK2B	psi-mi:“MI:0915”(physical association)	0.980
CSNK2B	CSNK2A1	psi-mi:“MI:2364”(proximity)	0.980
CSNK2B	CSNK2A1	psi-mi:“MI:0915”(physical association)	0.980
HEXIM1	CCNT1	psi-mi:“MI:0914”(association)	0.930
CSNK2A1	CSNK2A2	psi-mi:“MI:0914”(association)	0.920
PCGF5	CSNK2A2	psi-mi:“MI:0914”(association)	0.880
POLR2E	POLR3A	psi-mi:“MI:0914”(association)	0.870
CSNK2A1	RNF111	psi-mi:“MI:0915”(physical association)	0.850
RNF111	CSNK2A1	psi-mi:“MI:0915”(physical association)	0.850
RYBP	BMI1	psi-mi:“MI:0914”(association)	0.850
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
NRP1	CSNK2A2	psi-mi:“MI:0914”(association)	0.790
CSNK2A1	STAC3	psi-mi:“MI:0915”(physical association)	0.780
THAP1	CSNK2A1	psi-mi:“MI:0915”(physical association)	0.780
STAC3	CSNK2A1	psi-mi:“MI:0915”(physical association)	0.780
CSNK2A1	THAP1	psi-mi:“MI:0915”(physical association)	0.780
SIRT1	CSNK2A1	psi-mi:“MI:0915”(physical association)	0.770
CSNK2A1	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.760
HEXIM2	AHCYL1	psi-mi:“MI:0914”(association)	0.740
VSX1	USP12	psi-mi:“MI:0914”(association)	0.730
CSNK2A1	NFYA	psi-mi:“MI:0915”(physical association)	0.670

BioGRID (1570): AKT1 (Biochemical Activity), SGT1 (Biochemical Activity), SUGT1 (Biochemical Activity), MAGEA11 (Two-hybrid), NFYA (Two-hybrid), RNF111 (Two-hybrid), THAP1 (Two-hybrid), STAC3 (Two-hybrid), CSNK2A1 (Affinity Capture-Western), CSNK2A1 (Affinity Capture-MS), CSNK2A1 (Affinity Capture-MS), CSNK2A1 (Affinity Capture-MS), DAXX (Biochemical Activity), NOP58 (Biochemical Activity), RNF7 (Biochemical Activity)

ESM2 similar proteins: A2YNT8, A2ZAB5, A9TF79, O54833, O64812, O76484, P0C5D6, P19784, P20427, P21869, P28523, P31748, P31749, P31750, P43291, P43292, P47196, P49136, P49137, P49138, P49139, P68399, P68400, Q01314, Q02066, Q0D4J7, Q16644, Q2QY53, Q39192, Q39193, Q3SYZ2, Q3UMW7, Q5N942, Q66H84, Q6P9R2, Q6ZI44, Q6ZLP5, Q75H77, Q75LR7, Q75V57

Diamond homologs: A0A194WDG1, A8WIP6, A8X5H5, B0Y4X4, B6F107, C4YGK0, G4N374, G4NH08, O04160, O08911, O13352, O23145, O42376, O54833, O61847, O64816, O64817, O76484, O94737, P00546, P08181, P14681, P15790, P18265, P18266, P18334, P19139, P19454, P19784, P20427, P21868, P21869, P23111, P24100, P28020, P28523, P28547, P29618, P29619, P33674

SIGNOR signaling

200 interactions.

A	Effect	B	Mechanism
CSNK2A1	“up-regulates activity”	CAV2	phosphorylation
CSNK2A1	up-regulates	RNF7	phosphorylation
CSNK2A1	up-regulates	WAS	phosphorylation
CSNK2A1	“up-regulates activity”	LIG1	phosphorylation
CSNK2A1	“down-regulates activity”	CDC34	phosphorylation
CSNK2A1	up-regulates	HDAC1	phosphorylation
CSNK2A1	up-regulates	STX1A	phosphorylation
CSNK2A1	up-regulates	VAMP4	phosphorylation
CSNK2A1	up-regulates	PKD2	phosphorylation
CSNK2A1	up-regulates	PTGES3	phosphorylation
CSNK2A1	down-regulates	CDC25C	phosphorylation
CSNK2A1	up-regulates	DEK	phosphorylation
CSNK2A1	up-regulates	XRCC1	phosphorylation
CSNK2A1	up-regulates	TLE1	phosphorylation
CSNK2A1	down-regulates	GRIN2B	phosphorylation
CSNK2A1	“down-regulates activity”	HNRNPC	phosphorylation
CSNK2A1	up-regulates	LEF1	phosphorylation
CSNK2A1	up-regulates	CDK1	phosphorylation
CSNK2A1	up-regulates	AKT1	phosphorylation
CSNK2A1	up-regulates	CAPZA1	phosphorylation
CSNK2A1	down-regulates	ARNT	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 171 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	10	29.2×	6e-10
PTEN Regulation	8	17.7×	2e-06
Transcriptional Regulation by E2F6	6	17.1×	1e-04
Regulation of PTEN gene transcription	9	15.6×	1e-06
Oncogenic MAPK signaling	5	12.1×	3e-03
Transcriptional regulation by RUNX1	6	8.5×	3e-03
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	6	8.5×	3e-03
Signaling by BRAF and RAF1 fusions	5	8.3×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	13.3×	6e-03
mRNA splicing, via spliceosome	9	5.5×	6e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

281 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	35
Likely pathogenic	35
Uncertain significance	91
Likely benign	50
Benign	24

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1033456	NM_177559.3(CSNK2A1):c.376del (p.Gln126fs)	Pathogenic
1329650	NM_177559.3(CSNK2A1):c.838C>T (p.Arg280Ter)	Pathogenic
1675245	NM_177559.3(CSNK2A1):c.142G>A (p.Gly48Ser)	Pathogenic
1690320	NM_177559.3(CSNK2A1):c.832C>T (p.Arg278Ter)	Pathogenic
1709571	NM_177559.3(CSNK2A1):c.127C>T (p.Arg43Ter)	Pathogenic
1801973	NM_177559.3(CSNK2A1):c.61C>T (p.Arg21Ter)	Pathogenic
224797	NM_177559.3(CSNK2A1):c.824+2T>C	Pathogenic
224799	NM_177559.3(CSNK2A1):c.524A>G (p.Asp175Gly)	Pathogenic
224800	NM_177559.3(CSNK2A1):c.149A>C (p.Tyr50Ser)	Pathogenic
2442654	NM_177559.3(CSNK2A1):c.102-2A>G	Pathogenic
2503390	NM_177559.3(CSNK2A1):c.213+1G>T	Pathogenic
2504560	NM_177559.3(CSNK2A1):c.523G>A (p.Asp175Asn)	Pathogenic
2663860	NM_177559.3(CSNK2A1):c.572G>A (p.Arg191Gln)	Pathogenic
280816	NM_177559.3(CSNK2A1):c.139C>G (p.Arg47Gly)	Pathogenic
3340574	NM_177559.3(CSNK2A1):c.151A>C (p.Ser51Arg)	Pathogenic
3370910	NM_177559.3(CSNK2A1):c.920_921dup (p.Asp308fs)	Pathogenic
3385354	NM_177559.3(CSNK2A1):c.224dup (p.Lys76fs)	Pathogenic
3391482	NM_177559.3(CSNK2A1):c.524A>C (p.Asp175Ala)	Pathogenic
3774820	NM_177559.3(CSNK2A1):c.467A>G (p.Asp156Gly)	Pathogenic
3777315	NM_177559.3(CSNK2A1):c.214-1G>A	Pathogenic
3899537	NM_177559.3(CSNK2A1):c.589T>G (p.Phe197Val)	Pathogenic
392940	NM_177559.3(CSNK2A1):c.426+1G>T	Pathogenic
4082413	NM_177559.3(CSNK2A1):c.581C>T (p.Ser194Phe)	Pathogenic
421395	NM_177559.3(CSNK2A1):c.468T>A (p.Asp156Glu)	Pathogenic
4282412	NM_177559.3(CSNK2A1):c.152G>T (p.Ser51Ile)	Pathogenic
4531756	NM_177559.3(CSNK2A1):c.538G>A (p.Glu180Lys)	Pathogenic
4819102	NM_177559.3(CSNK2A1):c.829_847del (p.Ser277fs)	Pathogenic
4819106	NM_177559.3(CSNK2A1):c.254del (p.Leu85fs)	Pathogenic
4849518	NM_177559.3(CSNK2A1):c.546T>G (p.Tyr182Ter)	Pathogenic
521073	NM_177559.3(CSNK2A1):c.783C>A (p.Tyr261Ter)	Pathogenic

SpliceAI

2222 predictions. Top by Δscore:

Variant	Effect	Δscore
20:486371:CTGA:C	donor_loss	1.0000
20:486372:TGA:T	donor_loss	1.0000
20:486374:A:C	donor_loss	1.0000
20:486459:GTGT:G	acceptor_gain	1.0000
20:486463:C:CC	acceptor_gain	1.0000
20:487421:ACTCA:A	donor_loss	1.0000
20:487423:TCAC:T	donor_loss	1.0000
20:487424:CACAG:C	donor_loss	1.0000
20:487425:A:AC	donor_gain	1.0000
20:487425:ACAG:A	donor_loss	1.0000
20:487426:C:CA	donor_gain	1.0000
20:487426:CAGAA:C	donor_gain	1.0000
20:487442:C:CA	donor_gain	1.0000
20:487447:G:A	donor_gain	1.0000
20:487573:TGT:T	acceptor_gain	1.0000
20:487573:TGTC:T	acceptor_loss	1.0000
20:487574:GT:G	acceptor_gain	1.0000
20:487574:GTC:G	acceptor_loss	1.0000
20:487575:TC:T	acceptor_loss	1.0000
20:487576:C:CC	acceptor_gain	1.0000
20:487577:T:G	acceptor_loss	1.0000
20:488671:GACTT:G	donor_loss	1.0000
20:488672:ACTT:A	donor_loss	1.0000
20:488673:CTT:C	donor_loss	1.0000
20:488674:TTA:T	donor_loss	1.0000
20:488675:T:TG	donor_loss	1.0000
20:488676:A:AC	donor_gain	1.0000
20:488676:ACCT:A	donor_loss	1.0000
20:488677:C:CC	donor_gain	1.0000
20:488677:CCTG:C	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000058052 (20:481617 T>C), RS1000083409 (20:519087 C>T), RS1000135942 (20:540815 T>C), RS1000147092 (20:474791 T>G), RS1000215208 (20:531689 T>C), RS1000226196 (20:494156 T>C), RS1000270290 (20:541178 G>A,C), RS1000356280 (20:512365 A>C), RS1000420069 (20:478184 T>C), RS1000469273 (20:542112 G>A), RS1000473767 (20:543571 C>T), RS1000478280 (20:506476 G>C), RS1000545073 (20:503050 C>A,T), RS1000549050 (20:496338 G>A), RS1000557067 (20:495916 T>C,G)

Disease associations

OMIM: gene MIM:115440 | disease phenotypes: MIM:617062, MIM:615895

GenCC curated gene-disease

Disease	Classification	Inheritance
Okur-Chung neurodevelopmental syndrome	Definitive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
syndromic intellectual disability	Definitive	AD

Mondo (6): Okur-Chung neurodevelopmental syndrome (MONDO:0014893), intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092), epilepsy (MONDO:0005027), polyglucosan body myopathy 1 with or without immunodeficiency (MONDO:0014389), autism spectrum disorder (MONDO:0005258)

Orphanet (5): Okur-Chung neurodevelopmental syndrome (Orphanet:689422), Autoinflammatory syndrome with pyogenic bacterial infection and amylopectinosis (Orphanet:329173), Polyglucosan body myopathy type 1 (Orphanet:397937), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), NON RARE IN EUROPE: Autism (Orphanet:106)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST003542_11	Night sleep phenotypes	8.000000e-08
GCST003542_24	Night sleep phenotypes	4.000000e-07
GCST005024_26	Pursuit maintenance gain	8.000000e-06
GCST012490_24	Femur bone mineral density x serum urate levels interaction	1.000000e-12
GCST012490_353	Femur bone mineral density x serum urate levels interaction	4.000000e-13

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008433	pursuit maintenance gain measurement
EFO:0004531	urate measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2095191 (PROTEIN COMPLEX GROUP), CHEMBL3038477 (PROTEIN COMPLEX), CHEMBL3629 (SINGLE PROTEIN), CHEMBL3832943 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

36 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 421,627 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL1789941	RUXOLITINIB	4	11,547
CHEMBL189963	PALBOCICLIB	4	13,102
CHEMBL2005186	BELUMOSUDIL	4	1,817
CHEMBL3301610	ABEMACICLIB	4	7,045
CHEMBL502835	NINTEDANIB	4	8,545
CHEMBL535	SUNITINIB	4	79,020
CHEMBL608533	MIDOSTAURIN	4	7,259
CHEMBL58	MITOXANTRONE	4	166,878
CHEMBL50	QUERCETIN	3	74,559
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL483158	ALISERTIB	3	2,305
CHEMBL522892	DOVITINIB	3	4,944
CHEMBL603469	LESTAURTINIB	3
CHEMBL91829	RUBOXISTAURIN	3	77
CHEMBL3265032	ENTOSPLETINIB	3	1,628
CHEMBL1230165	SILMITASERTIB	2	593
CHEMBL31574	FISETIN	2	7,745
CHEMBL6246	ELLAGIC ACID	2	23,148
CHEMBL105442	CI-1040	2	3,936
CHEMBL1232461	MOLIBRESIB	2
CHEMBL1721885	SU-014813	2
CHEMBL1738758	ONVANSERTIB	2
CHEMBL230011	TG100-115	2
CHEMBL475251	R-406	2
CHEMBL572878	TOZASERTIB	2
CHEMBL151	LUTEOLIN	2
CHEMBL8260	BAICALEIN	2
CHEMBL83628	CHROMOCARB	2
CHEMBL1084546	PF-00562271	1

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Casein kinase 2 (CK2) family

Most potent curated ligand interactions (4 total), top 4:

Ligand	Action	Affinity	Parameter
silmitasertib	Inhibition	9.0	pIC50
compound 1a [PMID: 24900749]	Inhibition	8.0	pIC50
KDX1381	Binding	7.27	pKd
compound 2c [PMID: 22115617]	Inhibition	7.08	pKi

Binding affinities (BindingDB)

344 measured of 1578 human assays (1583 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
5-[[4-[(1,5-dimethyl-1,2,4-triazol-3-yl)amino]-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-1-methylindazole-3-carbonitrile	IC50	0.13 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl N-[(3S,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-fluoropiperidin-4-yl]carbamate	IC50	0.14 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[(3-cyano-1-methylindazol-5-yl)amino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.15 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-(hydroxymethyl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.16 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-(3-hydroxypyrrolidin-1-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.17 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[3-(3-methoxypyrrolidin-1-yl)azetidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.21 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[3-(1-acetylpiperidin-4-yl)-2-chloro-5-cyanoanilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.21 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-[(1,1-dioxothiolan-3-yl)amino]piperidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.22 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[[3-cyano-1-[1-[(2R)-2-hydroxypropyl]piperidin-4-yl]indazol-5-yl]amino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.22 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-(morpholin-4-ylamino)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.23 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-(2-chloro-5-cyano-3-ethenylanilino)-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.23 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[3-(3-methylsulfonylpyrrolidin-1-yl)azetidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.24 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl N-[(3S,4R)-1-[1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]azetidin-3-yl]-4-methylpyrrolidin-3-yl]carbamate	IC50	0.27 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl N-[(3R,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-phosphonooxypiperidin-4-yl]carbamate	IC50	0.27 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[[3-cyano-1-[1-[(2S)-2-hydroxypropyl]piperidin-4-yl]indazol-5-yl]amino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.27 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[3-[1-(1-acetylazetidin-3-yl)piperidin-4-yl]-2-chloro-5-cyanoanilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.28 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-(oxolan-3-yl)piperazin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.29 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
4-chloro-3-[[4-(cyclopropylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-5-[6-fluoro-4-(oxetan-3-yl)-1,4-diazepan-1-yl]benzonitrile	IC50	0.29 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-[(2R)-2-hydroxypropyl]piperazin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.3 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-[(3-hydroxycyclobutyl)amino]piperidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.3 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[3-(3-hydroxyazetidin-1-yl)azetidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.3 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-(1-methyl-3,6-dihydro-2H-pyridin-4-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	0.31 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
3-[[4-(cyclopropylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-4-fluoro-5-[3-(4-methylpiperazin-1-yl)azetidin-1-yl]benzonitrile	IC50	0.39 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl N-[(3R,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]carbamate	IC50	0.41 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
5-(4-chlorophenyl)benzo[c]2,6-naphthyridine-8-carboxylic acid (Compound 12)	IC50	0.5 nM
methyl N-[(3S,4S)-1-[2-chloro-5-cyano-3-[[4-(ethylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]carbamate	IC50	0.52 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl N-[(3S,4S)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]carbamate	IC50	0.72 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
CX-5279	IC50	0.91 nM
methyl N-[(3S,4S)-1-[1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]piperidin-4-yl]-4-methylpyrrolidin-3-yl]carbamate	IC50	1.31 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[[1-(oxetan-3-yl)piperidin-4-yl]amino]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.32 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
4-chloro-3-[[4-(ethylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-5-[4-[[(2R)-2-hydroxypropyl]amino]piperidin-1-yl]benzonitrile	IC50	1.33 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[3-[1-[3,3-bis(hydroxymethyl)cyclobutyl]piperidin-4-yl]-2-chloro-5-cyanoanilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.34 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
methyl 4-[4-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]piperazin-1-yl]piperidine-1-carboxylate	IC50	1.35 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
oxetan-3-yl 4-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]piperidine-1-carboxylate	IC50	1.35 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
oxetan-3-yl N-[(3R,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]carbamate	IC50	1.36 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
4-chloro-3-[[4-(cyclopropylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-5-[4-[(3,3-difluorocyclobutyl)amino]piperidin-1-yl]benzonitrile	IC50	1.37 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
N-[(3R,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]-2-(4-methylpiperazin-1-yl)acetamide	IC50	1.37 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[3-[(4aR,8aR)-1-(oxetan-3-yl)-3,4a,5,7,8,8a-hexahydro-2H-pyrido[3,4-b][1,4]oxazin-6-yl]-2-chloro-5-cyanoanilino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.37 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-(oxetan-3-yl)piperazin-1-yl]anilino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.39 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-(2,2-difluoroethyl)piperazin-1-yl]anilino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.39 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.4 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
4-chloro-3-[[4-(cyclopropylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-5-[3-(morpholine-4-carbonyl)-4-(oxetan-3-yl)piperazin-1-yl]benzonitrile	IC50	1.4 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-(difluoromethyl)-3-[4-(3-methyloxetan-3-yl)piperazin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.42 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
4-chloro-3-[[4-(ethylamino)-7-isocyanoimidazo[2,1-f][1,2,4]triazin-2-yl]amino]-5-piperidin-4-ylbenzonitrile	IC50	1.42 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-(2-methylsulfonylethyl)piperazin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.44 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[[3-cyano-1-[1-(oxetan-3-yl)piperidin-4-yl]indazol-5-yl]amino]-4-(ethylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.44 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-(difluoromethyl)-3-[4-(1-methylazetidin-3-yl)piperazin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.5 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
CX-4945	IC50	1.5 nM
2-methoxyethyl N-[(3R,4R)-1-[2-chloro-5-cyano-3-[[7-cyano-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazin-2-yl]amino]phenyl]-3-hydroxypiperidin-4-yl]carbamate	IC50	1.53 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors
2-[2-chloro-5-cyano-3-[4-[(3-cyanocyclobutyl)amino]piperidin-1-yl]anilino]-4-(cyclopropylamino)imidazo[2,1-f][1,2,4]triazine-7-carbonitrile	IC50	1.56 nM	US-8940736: Imidazotriazinecarbonitriles useful as kinase inhibitors

ChEMBL bioactivities

2359 potent at pChembl≥5 of 2534 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.89	Kd	0.01288	nM	CHEMBL4089961
10.80	Kd	0.016	nM	CHEMBL4089961
10.50	Kd	0.03162	nM	CHEMBL4077554
10.43	Kd	0.037	nM	CHEMBL4077554
10.32	Kd	0.0482	nM	CHEMBL3103191
10.08	Ki	0.084	nM	CHEMBL5419810
10.03	Kd	0.094	nM	CHEMBL4099729
10.03	Kd	0.09333	nM	CHEMBL4099729
9.89	IC50	0.13	nM	CHEMBL3699289
9.85	IC50	0.14	nM	CHEMBL3699277
9.82	IC50	0.15	nM	CHEMBL3699234
9.80	IC50	0.16	nM	CHEMBL3699295
9.79	Kd	0.1622	nM	CHEMBL4075338
9.77	IC50	0.17	nM	CHEMBL3699235
9.77	Kd	0.17	nM	CHEMBL4075338
9.68	IC50	0.21	nM	CHEMBL3699253
9.68	IC50	0.21	nM	CHEMBL3699266
9.66	IC50	0.22	nM	CHEMBL3699292
9.66	IC50	0.22	nM	CHEMBL3699244
9.64	IC50	0.23	nM	CHEMBL3699294
9.64	IC50	0.23	nM	CHEMBL3699237
9.64	IC50	0.23	nM	CHEMBL4848224
9.62	IC50	0.24	nM	CHEMBL3699252
9.59	Ki	0.26	nM	CHEMBL398149
9.57	IC50	0.27	nM	CHEMBL3699291
9.57	IC50	0.27	nM	CHEMBL3699254
9.57	IC50	0.27	nM	CHEMBL3699276
9.55	IC50	0.28	nM	CHEMBL3699280
9.54	IC50	0.29	nM	CHEMBL3699238
9.54	IC50	0.29	nM	CHEMBL3699278
9.52	IC50	0.3	nM	CHEMBL3699255
9.52	IC50	0.3	nM	CHEMBL3699250
9.52	IC50	0.3	nM	CHEMBL3699239
9.51	IC50	0.31	nM	CHEMBL3699262
9.47	Kd	0.34	nM	CHEMBL4162173
9.46	Ki	0.35	nM	CHEMBL230354
9.42	Ki	0.38	nM	SILMITASERTIB
9.42	Kd	0.38	nM	SILMITASERTIB
9.41	IC50	0.39	nM	CHEMBL3699287
9.40	Kd	0.4	nM	CHEMBL4075701
9.40	Kd	0.4	nM	CHEMBL4169451
9.39	IC50	0.41	nM	CHEMBL3699256
9.38	Kd	0.42	nM	CHEMBL4069112
9.38	Kd	0.4169	nM	CHEMBL4069112
9.38	Ki	0.42	nM	CHEMBL4846181
9.38	Ki	0.42	nM	CHEMBL1682283
9.34	IC50	0.46	nM	CHEMBL4862003
9.30	Kd	0.5	nM	CHEMBL4061407
9.30	IC50	0.5	nM	SILMITASERTIB
9.28	IC50	0.52	nM	CHEMBL3699282

PubChem BioAssay actives

1178 with measured affinity, of 4321 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(E,3E)-3-[2-[4-[[(5S)-5-carboxy-5-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[9-(8-carboxybenzo[c][2,6]naphthyridin-5-yl)oxynonanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]pentyl]amino]-4-oxobutyl]-1-ethyl-2-methyl-6-sulfoindol-3-ylidene]prop-1-enyl]-1-ethyl-3,3-dimethylindol-1-ium-5-sulfonate	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	<0.0001	uM
5-[9-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-5-amino-1-carboxypentyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-9-oxononoxy]benzo[c][2,6]naphthyridine-8-carboxylic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	<0.0001	uM
N-[2-[2-aminoethyl(methyl)amino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301603: Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	kd	<0.0001	uM
N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-methylphenyl]acetamide	1301603: Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	kd	<0.0001	uM
N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]phenyl]acetamide	1301603: Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	kd	<0.0001	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[9-(8-carboxybenzo[c][2,6]naphthyridin-5-yl)oxynonanoylamino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0001	uM
(2S)-6-amino-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2R)-3-carboxy-2-[8-(4,5,6,7-tetraiodobenzimidazol-1-yl)octanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoic acid	2028056: Binding affinity to CK2 (unknown origin) assessed as inhibition constant	ki	0.0001	uM
(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[9-[(8-carboxybenzo[c][2,6]naphthyridin-5-yl)amino]nonanoylamino]propanoyl]amino]propanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0002	uM
2-fluoroethyl 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0002	uM
4-[2-[[4-[[6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(1R)-5-amino-1-carboxypentyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-4-oxobutanoyl]amino]-1,3-selenazol-5-yl]benzoic acid	1362772: Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	kd	0.0003	uM
N-[3-[(4-anilino-8-cyanopyrazolo[1,5-a][1,3,5]triazin-2-yl)amino]phenyl]acetamide	291056: Inhibition of human CK2 alpha	ki	0.0003	uM
N-[3-[[8-cyano-4-(cyclopropylamino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]acetamide	291056: Inhibition of human CK2 alpha	ki	0.0003	uM
(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[9-(8-carboxybenzo[c][2,6]naphthyridin-5-yl)oxynonanoylamino]propanoyl]amino]propanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0004	uM
2-[(1E,3E,5E)-5-[2-[4-[[(5S)-5-carboxy-5-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[8-(4,5,6,7-tetrabromobenzimidazol-1-yl)octanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]pentyl]amino]-4-oxobutyl]-1-ethyl-2-methyl-6-sulfoindol-3-ylidene]penta-1,3-dienyl]-1-ethyl-3,3-dimethylindol-1-ium-5-sulfonate	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0004	uM
5-[[(5R)-5-carboxy-5-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[6-[[4-[[5-(4-carboxyphenyl)-1,3-thiazol-2-yl]amino]-4-oxobutanoyl]amino]hexanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]pentyl]carbamoyl]-2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate	1362772: Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	kd	0.0004	uM
5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid	1294144: Inhibition of recombinant human CK2 holoenzyme using RRRDDDSDDD as substrate measured after 20 mins at 30 degC by radiometric kinase assay in presence of [gamma-32P]ATP	ki	0.0004	uM
5-(3-cyanoanilino)pyrimido[4,5-c]quinoline-8-carboxylic acid	1750468: Inhibition of CK2 (unknown origin)	ki	0.0004	uM
5-(3-ethynylanilino)pyrimido[4,5-c]quinoline-8-carboxylic acid	2028056: Binding affinity to CK2 (unknown origin) assessed as inhibition constant	ki	0.0004	uM
(2S)-6-amino-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[8-(4,5,6,7-tetrabromobenzimidazol-1-yl)octanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]hexanoic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0005	uM
2-[(1E,3E,5E)-5-[2-[4-[[(5S)-5-[9-(8-carboxybenzo[c][2,6]naphthyridin-5-yl)oxynonanoylamino]-6-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1S)-1,2-dicarboxyethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-4-oxobutyl]-1-ethyl-2-methyl-6-sulfoindol-3-ylidene]penta-1,3-dienyl]-1-ethyl-3,3-dimethylindol-1-ium-5-sulfonate	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0005	uM
5-(4-chlorophenyl)benzo[c][2,6]naphthyridine-8-carboxylic acid	1801077: Molecular Docking from Article 10.1111/cbdd.12372: “Structural basis for low-affinity binding of non-R2 carboxylate-substituted tricyclic quinoline analogs to CK2a: comparative molecular dynamics simulation studies.”	ic50	0.0005	uM
5-(3-chloroanilino)-N-(2-morpholin-4-ylethyl)benzo[c][2,6]naphthyridine-8-carboxamide	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0005	uM
4-[2-[[4-[[6-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(1R)-5-amino-1-carboxypentyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-4-oxobutanoyl]amino]-1,3-thiazol-5-yl]benzoic acid	1362772: Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	kd	0.0006	uM
2,2-difluoroethyl 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0006	uM
2-hydroxyethyl 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0006	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[9-(8-carboxy-5-oxobenzo[c][2,6]naphthyridin-6-yl)nonanoylamino]hexanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0007	uM
5-(3-chloroanilino)-N-(2-hydroxyethyl)benzo[c][2,6]naphthyridine-8-carboxamide	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0007	uM
5-[[(5R)-5-carboxy-5-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[[(2R)-3-carboxy-2-[6-[[4-[[5-(4-carboxyphenyl)-1,3-selenazol-2-yl]amino]-4-oxobutanoyl]amino]hexanoylamino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]pentyl]carbamoyl]-2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate	1362772: Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	kd	0.0008	uM
2-iodoethyl 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0008	uM
methyl 3-[[5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carbonyl]amino]propanoate	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0008	uM
N-(2-aminoethyl)-5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxamide	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0009	uM
3-(cyclopropylamino)-5-[3-(trifluoromethyl)anilino]pyrimido[4,5-c]quinoline-8-carboxylate	1799832: Phosphorylation Assay from Article 10.1021/bi2008382: “Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.”	ic50	0.0009	uM
5-(4-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid	566117: Inhibition of human recombinant CK2 assessed as inhibition of [gamma33P]ATP incorporation into substrate by luminescence assay	ic50	0.0010	uM
5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylate	1799832: Phosphorylation Assay from Article 10.1021/bi2008382: “Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.”	ic50	0.0015	uM
(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[7-(8-carboxybenzo[c][2,6]naphthyridin-5-yl)oxyheptanoylamino]propanoyl]amino]propanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0016	uM
5-[[8-(hydroxyamino)-8-oxooctyl]amino]benzo[c][2,6]naphthyridine-8-carboxylic acid;2,2,2-trifluoroacetic acid	1652189: Inhibition of human recombinant CK2 using RRRDDDSDDD peptide as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by ADP-Glo kinase assay	ic50	0.0017	uM
5-[4-[2-aminoethyl(ethyl)amino]-3-(1,2,4-triazol-4-yl)anilino]-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidine-3-carbonitrile	2066662: Inhibition of CSNK2A1 (unknown origin) in presence of ATP by Eurofins radiometric enzymatic assay	ic50	0.0017	uM
N-(2-bromoethyl)-5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxamide	1750390: Inhibition of human CK2 incubated for 2 hrs	ic50	0.0018	uM
N-[3-[[8-cyano-4-(cyclobutylamino)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino]phenyl]acetamide	291056: Inhibition of human CK2 alpha	ki	0.0019	uM
N-(3-ethynylphenyl)-6-(1H-1,2,4-triazol-5-yl)thieno[3,2-c]quinolin-4-amine	657060: Inhibition of human recombinant CK2 (alphaalpha-betabeta) holoenzyme using RRRDDDSDDD as substrate and 15 uM ATP by radiometric assay	ic50	0.0020	uM
5-(3-ethynylanilino)pyrimido[4,5-c]quinoline-8-carboxylate	1799832: Phosphorylation Assay from Article 10.1021/bi2008382: “Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.”	ic50	0.0021	uM
(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-3-carboxy-2-[9-(8-carboxy-5-oxobenzo[c][2,6]naphthyridin-6-yl)nonanoylamino]propanoyl]amino]propanoyl]amino]butanedioic acid	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0024	uM
2-[(1E,3E,5E)-5-[2-[4-[[(5S)-6-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(2S)-3-carboxy-1-[[(1S)-1,2-dicarboxyethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-[9-(8-carboxy-5-oxobenzo[c][2,6]naphthyridin-6-yl)nonanoylamino]-6-oxohexyl]amino]-4-oxobutyl]-1-ethyl-2-methyl-6-sulfoindol-3-ylidene]penta-1,3-dienyl]-1-ethyl-3,3-dimethylindol-1-ium-5-sulfonate	1481164: Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	kd	0.0024	uM
4-(6,8-dibromo-3-hydroxy-4-oxochromen-2-yl)benzoic acid	2028061: Inhibition of human recombinant CK2 using RRRDDDSDDD peptide as substrate incubated for 20 mins in presence of [gamma-32p]-ATP and ATP by beta-counter analysis	ki	0.0025	uM
N-[2-[(3S)-3-aminopiperidin-1-yl]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM
N-[2-[[(2R)-2-aminopropyl]-methylamino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM
N-[2-[[(2S)-2-aminopropyl]-methylamino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM
N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-[methyl(2-morpholin-4-ylethyl)amino]phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM
N-[5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]-2-(3-hydroxypropylamino)phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM
N-[2-[2-aminoethyl(ethyl)amino]-5-[[3-cyano-7-(cyclopropylamino)pyrazolo[1,5-a]pyrimidin-5-yl]amino]phenyl]acetamide	1301597: Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	ic50	0.0030	uM

CTD chemical–gene interactions

81 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases methylation, increases expression, affects cotreatment, decreases expression	5
Cyclosporine	increases expression	3
Cadmium Chloride	increases expression, decreases expression	3
bisphenol A	affects expression, increases expression	2
sodium arsenite	increases expression	2
silmitasertib	affects phosphorylation, affects reaction, affects binding, decreases reaction, decreases activity	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects expression	2
Formaldehyde	affects localization, affects phosphorylation, decreases expression, affects reaction	2
Ozone	affects expression, affects cotreatment, increases oxidation, increases abundance	2
Quercetin	affects binding, decreases activity	2
Rotenone	increases cleavage, increases expression, increases lipidation, affects reaction, decreases expression	2
aristolochic acid I	increases expression	1
multi-kinase inhibitor 108600	affects folding, affects binding, decreases reaction, decreases activity	1
geldanamycin	increases expression	1
bufotalin	increases expression	1
alternariol	decreases activity	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pyrithione	affects binding, affects cotreatment, decreases reaction, increases reaction	1
salinomycin	decreases expression	1
decabromobiphenyl ether	decreases expression	1
quercitrin	affects expression	1
beta-lapachone	increases expression	1
arsenite	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
tetrabromobisphenol A	decreases expression	1
3,4,5,3’,4’-pentachlorobiphenyl	affects expression	1
ochratoxin A	decreases expression	1
benzo(e)pyrene	increases methylation	1
2,2’,3’,4,4’,5-hexachlorobiphenyl	affects expression	1

ChEMBL screening assays

1085 unique, capped per target: 937 binding, 146 functional, 2 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1020723	Binding	Inhibition of human CK2 at 10 umol/L	Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). — J Med Chem
CHEMBL620984	Functional	Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM	Casein kinase II inhibitors isolated from two Brazilian plants Hymenaea parvifolia and Wulffia baccata. — Bioorg Med Chem Lett
CHEMBL4407590	ADMET	Inhibition of recombinant human full-length His-tagged CSNK2A1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z’-lyte assay relative to control	Optimization and Mechanistic Characterization of Pyridopyrimidine Inhibitors of Bacterial Biotin Carboxylase. — J Med Chem

Cellosaurus cell lines

476 cell lines: 476 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0006	THP-1	Cancer cell line	Male
CVCL_0R21	THP-1/DC-SIGN	Cancer cell line	Male
CVCL_0R25	THP-1(NCI)	Cancer cell line	Male
CVCL_0R26	THP-1(NCI)/DC-SIGN	Cancer cell line	Male
CVCL_3426	THP-1h	Cancer cell line	Male
CVCL_3427	THP-1l	Cancer cell line	Male
CVCL_4V22	THP-1/ara-C	Cancer cell line	Male
CVCL_5115	A-THP-1	Cancer cell line	Male
CVCL_5I76	THP1-defCASP1	Cancer cell line	Male
CVCL_5I77	THP1-NLRC4	Cancer cell line	Male

Clinical trials (associated diseases)

298 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study